Daré Bioscience (DARE) Q2 2026 Earnings Report

The call described meaningful operational and clinical progress — a first product launch, an approaching prescription product with early prescription activity, positive Phase III interim data for Ovaprene, and non-dilutive funding supporting R&D. However, these positives are balanced by constrained near-term financials: modest Q2 revenue ($200k), limited cash ($12.6M) with a slight working capital deficit, a sizable deferred grant liability (~$15M), and ongoing net losses. Regulatory nuance around Ovaprene completers and the fact that DARE-VVA1 is not yet dispensing also add execution and timing risk. Overall, the update reflects promising commercial and clinical momentum but with material near-term financial and execution challenges.

The company guided toward disciplined commercial execution in 2026 with its first direct-to-market product (Flora Sync LF5, launched in June with sales recorded beginning July) and DARE‑VVA1 (prescription dispensing targeted to begin this quarter), while building a multi‑product revenue profile into 2027 (DARE‑HRT1 revenue targeted in 2027). Key metrics cited include Q2 cash of ~$12.6M (06/30/2026), a working capital deficit of ~$(200)K and a deferred grant liability of ~ $15M; Q2 revenue of $200K (vs. $(21)K prior year), SG&A ~$2.6M (vs. $2.4M), R&D ~$200K (vs. $1.4M), and net loss improving to ~$(3)M (vs. $(4)M). Clinical and commercial benchmarks: Flora Sync LF5 was evaluated in a 100‑patient randomized study and targets consumers in a market where ~65% of women 18–65 report concern about vaginal scent; DARE‑VVA1 addresses an estimated 20M U.S. women (a ~$2B opportunity at $99/tube ≈10 uses/tube) and is available initially via 503B compounding while pursuing 505(b)(2) approval; Ovaprene Phase III aims to enroll 400–500 participants (FDA amended to remove 250 completer expectation) to achieve ≥2,500 menstrual cycles of exposure with topline data in 2027; DARE‑HPV1 Phase II plans ~100 women with topline 2027 results and has received $2M total non‑dilutive funding to date.